INTRODUCTION {#s5}
============

Inflammatory bowel disease (IBD) is an immune-mediated disease causing chronic inflammation in the gastrointestinal (GI) tract. The disease entity is characterized by relapsing course of diarrhea, abdominal pain, and weight loss. The prevalence of IBD is approximately 0.5% in the Western world, and the prevalence and incidence of the disease entity is increasing globally.^[@CIT0001]^ Crohn's disease (CD) and ulcerative colitis (UC) represent the 2 main subtypes of the disease. The precise pathophysiology of IBD remains largely unknown, but accumulating evidence suggests that the dysregulated mucosal immune response is caused by a loss of tolerance toward gut microbiota in genetically susceptible individuals.^[@CIT0002]^

Historically, the influence of genetics was first illustrated by high concordance rates in family and twin studies.^[@CIT0003]^ During the last decades, large consortium-based meta-analyses of genome-wide association studies (GWAS) have dramatically increased our knowledge of the genetic architecture of IBD and its subtypes CD and UC. These analyses have also revealed that the genetic information might contribute to the classification of IBD patients into disease-specific subtypes, specifically in relation to the location of inflammation.^[@CIT0004]^ Interestingly, genetic risk effects often appear to be mediated by allelic differences (risk vs nonrisk variants) in the modulation of mRNA expression (expression quantitative trait loci \[eQTLs\]).

Even though the identification of genetic risk variants has largely improved our understanding of disease mechanisms in IBD, many genes and their encoded proteins are still functionally uncharacterized. Thus, the pace of protein characterization has been slower than that at the genetic level, and the repertoire and overall nature of the pool of IBD risk gene products ("IBD risk proteome") still remain largely unknown.

One initiative to increase our understanding of the proteome is the Human Protein Atlas (HPA) project, which aims at generating and applying antibodies to study all of the approximately 20,000 human proteins encoded in the genome.^[@CIT0005]^ The current version of the HPA (version 15) includes 25,039 antibodies targeting 17,005 proteins, most of which are annotated to relative expression data and cell- and tissue-specific localization ([www.proteinatlas.org](www.proteinatlas.org)).

In the present exploratory study, we took advantage of the HPA repository for the characterization of expression of the IBD risk proteome in human serum. In particular, we screened protein products encoded at IBD risk loci for their potential to distinguish IBD patients from healthy individuals and to further differentiate between different disease subtypes. We thus propose a list of IBD-associated protein targets that may be exploited in follow-up studies for future IBD profiling efforts.

METHODS {#s6}
=======

Study Population {#s7}
----------------

The IBD patients included in this study were obtained from a cohort previously described.^[@CIT0006]^ In short, adult patients with CD and UC were consecutively recruited at the outpatient IBD clinic of Örebro University Hospital, Sweden. After obtaining an informed written consent, blood samples were collected, and the serum was separated after centrifugation at 2400*g* for 6 minutes at room temperature. All serum samples were stored as aliquots at −80°C. Diagnosis was based on internationally accepted clinical, endoscopic, radiologic, and histologic criteria.^[@CIT0007]^ Medical notes were scrutinized to classify disease characteristics according the Montreal classification.^[@CIT0008]^ A random sample set of 49 CD patients, 51 UC patients, and 50 healthy blood donors (no history of chronic GI disease), matched according to sex and age ±5 years (sample set, IBD 1), was selected. In addition, 33 CD and 31 UC patients were selected to extend the analyses and explore possible differences between subgroups of CD and UC patients (sample set, IBD 2). Demographics and clinical characteristics of patients with IBD are reported in [Table 1](#T1){ref-type="table"}. None of the patients were included at disease onset, and only a few patients had early IBD, as illustrated by the information on disease duration in [Table 1](#T1){ref-type="table"}. The study was approved by the Örebro Regional Ethics Committee (2006/245).

###### 

Demographics and Clinical Characteristics of CD and UC Patients

                                          IBD 1         IBD 1        IBD 2        IBD 2
  --------------------------------------- ------------- ------------ ------------ -------------
  Male sex, No. (%)                       33 (67)       35 (69)      21 (68)      21 (64)
  Median (range) age at diagnosis, y      28 (10--54)   30 (5--61)   25 (7--46)   26 (12--65)
  Median (range) disease duration, y      20 (0--43)    15 (1--39)   17 (0--36)   10 (0--48)
  Disease location, No. (%)                                                       
   Ileal (L1)                             14 (29)                    5 (16)       
   Colonic (L2)                           14 (29)                    15 (48)      
   Ileocolonic (L3)                       21 (43)                    11 (35)      
   Upper disease (L4)                                                             
  Disease behavior, No. (%)                                                       
   Nonstricutring, nonpenetrating (B1)    18 (37)                    18 (58)      
   Stricturing (B2)                       21 (43)                    9 (29)       
   Penetrating (B3)                       10 (20)                    4 (13)       
   Perianal fistulas                      6 (12)                     7 (23)       
  Disease extent, No. (%)                                                         
   Proctitis (E1)                                       6 (12)                    7 (21)
   Left-sided colitis (E2)                              23 (45)                   10 (30)
   Extensive colitis (E3)                               22 (43)                   16 (48)
  Clinical disease activity, No. (%)^a^                                           
   Remission                              34 (69)       39 (76)      23 (74)      26 (79)
   Active                                 14 (29)       12 (24)      8 (26)       7 (21)
  Medications, No. (%)^b^                                                         
   5ASA/SASP (local or oral)              8 (16)        25 (49)      3 (10)       16 (48)
   Corticosteroids (local or oral)        7 (14)        8 (16)       6 (19)       7 (21)
   Thiopurines                            12 (24)       13 (25)      9 (29)       4 (12)
   Methotrexate                           2 (4)         2 (4)        3 (10)       1 (3)
   Anti-TNF                               1 (2)         0 (0)        3 (10)       0 (0)
   No drugs                               24 (49)       12 (24)      13 (42)      12 (36)
  Previous surgical resection, No. (%)    34 (69)       6 (12)       15 (48)      3 (9)

Abbreviations: 5ASA/SASP, 5-aminosalicylates/sulfasalazine; anti-TNF, anti--tumor necrosis factor.

^a^Data on disease activity were not available in 1 patient with Crohn's disease in IBD 1.

^b^Some patients were in a combination of different treatments: IBD 1 CD, n = 3; IBD 1 UC, n = 8; IBD 2 CD, n = 6; IBD 2 UC, n = 6.

Experimental Strategy {#s8}
---------------------

To characterize IBD risk proteome serum expression profiles in patients and controls, we applied an affinity proteomic analysis targeting proteins encoded at known IBD risk loci.^[@CIT0009]^ In addition, a small subset of proteins known to be involved in inflammation, including neutrophil regulation, was added as "experimental controls."^[@CIT0010]^ Quality assessment was followed by data analyses based on univariate and multivariate approaches, and a brief outline is reported in [Figure 1](#F1){ref-type="fig"}.

![Schematic description of study. Target selection was made based on the risk loci GWAS hits (n = 163). Thirteen additional proteins involved in inflammation, including neutrophil regulation, were added as "experimental controls." From these, antibodies available from the Human Protein Atlas were selected to compose a targeted SBA. Two sample sets, denoted IBD 1 and IBD 2, were then screened using this bead array. Upon data processing, both uni- and multivariate analyses were performed to propose targets of interest. Comparisons of IBD patients and subgroups of patients vs healthy controls were performed based on sample set IBD 1, and for comparisons between subgroups of patients, both sample sets (ie, IBD 1 and IBD 2) were used.](izy32601){#F1}

Antibody Bead Array Assay {#s9}
-------------------------

### Antibody selection and bead coupling {#s10}

The HPA library (version 15) was screened to identify antibodies targeting any of the 1438 predicted protein products encoded at the 163 IBD risk loci (known at the time the study was initiated).^[@CIT0009]^ From the 601 thereby identified, final selection of antibodies suitable for suspension bead arrays (SBAs) was based on availability, binding specificity assessed by protein arrays,^[@CIT0011]^ and concentration (\>0.05 mg/mL). This yielded a total of 343 antibodies directed against 205 unique target proteins, corresponding to 104 of the 163 IBD risk loci, which are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, together with a small "control" selection of 22 antibodies directed against 13 known neutrophil- and inflammation-associated proteins.

Antibodies were then coupled to magnetic color-coded microspheres (MagPlex, Luminex Corp.) and assessed for coupling efficiency, and SBAs were generated as previously described.^[@CIT0012]^ Rabbit antihuman albumin (Dako) and donkey antihuman IgG (Jackson ImmunoResearch Laboratories) antibodies were used as controls for sample transfer, whereas rabbit IgG (Jackson ImmunoResearch Laboratories) and bare beads served as negative controls.

### Sample randomization and bead array processing {#s11}

Before the analysis, serum samples were randomized and distributed into their assigned microtiter plate positions using a liquid handling device (Freedom EVO150, Tecan). Serum aliquots were then diluted 1:10 in PBS and labeled using NHS-PEO4-biotin (Pierce). The labeled samples were diluted 1:50 in assay buffer and heat-treated at 56°C for 30 minutes before being combined with the suspension bead array. Details about this protocol have been described previously.^[@CIT0013]^ Transfer of liquid volumes \<5 µL into and between plates was performed with a liquid handling device (CyBi-SELMA, CyBio). To avoid location effects because of the sequential read-out of plates,^[@CIT0014]^ diluted samples were randomized across two 384-well plates to obtain a similar distribution of sample sets, age, and sex. In addition, each 384-well plate contained 24 samples (16 repeated pooled serum samples and 8 samples containing only buffer) to assess technical variance. The 2 assay plates were processed in parallel. The beads were washed in 1x PBS with 1% Tween20 using a plate washer (EL406, Biotek). Lastly, median fluorescence intensity (MFI) levels were obtained for each antibody-coupled bead using Flexmap 3D instruments (Luminex Corp.), accepting a minimum of 35 events for each bead ID.

### Antibody validation {#s12}

A description of methods used for antibody validation can be found in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.

Data Processing and Analysis {#s13}
----------------------------

### Data preprocessing {#s14}

For data evaluation, processing, and analysis, the statistical environment R^[@CIT0015]^ was used unless otherwise stated. For quality assessment via calculations of coefficient of variations (CV), unprocessed data were employed. Antibodies revealing average MFI levels lower than rabbit IgG (negative control) or higher than anti-albumin (positive control) were removed. Further investigations involved data that were processed with multidimensional MA normalization^[@CIT0016]^ after exclusion of data generated from sample-free assay buffer, reference sample pools, and the removal of outliers based on robust principal component analysis.^[@CIT0017]^

### Univariate comparisons {#s15}

For each antibody profile, a linear regression model with adjustment for age and sex was used to find profiles that could separate IBD patients from healthy controls, CD patients from healthy controls, or UC patients from healthy controls in the IBD 1 sample set. Comparisons of CD patients vs UC patients were performed on both sample sets (IBD 1 and IBD 2), and results were merged by a fixed-effects model for meta-analysis using the "meta" package in R.^[@CIT0018]^ The q-value approach to false discovery rate (FDR) estimation^[@CIT0019]^ was used to account for multiple testing. To shortlist candidate proteins for comparison of patients vs healthy controls, we used an FDR cutoff at q \< 0.01, whereas a less stringent cutoff of q \< 0.05 was used for comparing UC vs CD.

### Multivariate analysis {#s16}

To identify differentially expressed signatures of proteins, a multivariate approach was applied. Multivariate classification analysis was implemented as sparse partial least squares (sPLS) analysis^[@CIT0020]^ for the same comparisons as in the univariate analysis. Data from both sample sets (IBD 1 and IBD 2) were merged to obtain a data set large enough for a rigorous double cross-validation approach (described below). Data were quantile-normalized using the R package "limma" before analysis.^[@CIT0021]^ After model fitting, variable importance was calculated as a variable importance in projection (VIP) value^[@CIT0022]^ for each protein in each of the group comparisons: (1) IBD patients vs healthy controls, (2) CD patients vs healthy controls, (3) UC patients vs healthy controls, (4) CD patients vs UC patients, (5) colonic (L2) CD patients vs UC patients, and (6) ileal (L1/L3) CD patients vs UC patients. VIP was calculated for all variables, and the analyses were optimized for both the number of variables and the number of components to use in the respective prediction model, within the inner cross-validation loop.^[@CIT0023],\ [@CIT0024]^ The prediction models were validated, applying the outer leave-one-out cross-validation (LOO) approach, and hit rates were collected. Significance of the observed LOO hit rates was established by resampling analyses, that is, randomly permuting the class labels and re-running the double cross-validation analyses (including inner loops and optimizations) to be able to calculate permutation *P* values for the observed LOO prediction hit rates for the original data.

RESULTS {#s17}
=======

Data Quality Assessment {#s18}
-----------------------

At first, we assessed the overall quality of the data and determined the coefficient of variation (CV) of each antibody in replicated and independent samples. As shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, the CVs of technical reproducibility (tCVs), calculated from the replicated reference sample pools, were \<10% in 279 of 365 antibodies (76%). A denoted biological CV (bCV), describing the variation across all other samples, was also calculated. The median tCVs (9%) were substantially lower when compared with the bCVs (\>37%), indicating that the variability in the data set is due to biological differences and not technical artifacts. For the subsequent analyses, antibodies with tCV \<15% were included (n = 355). These antibodies were directed against 204 proteins, encoded at 104 genetic risk loci. We did not identify any sample outliers when applying robust PCA analyses (not shown).

Identification of Differentially Abundant Proteins {#s19}
--------------------------------------------------

### Univariate analysis {#s20}

To identify single proteins associated with IBD and subtypes of the disease, univariate analyses were performed. Using the data set IBD 1, the comparison IBD (CD and UC) vs healthy controls yielded significant results for 13 antibodies ([Table 2](#T2){ref-type="table"}), and the relative abundance of the 4 top-ranking antibodies is illustrated in [Figure 2A](#F2){ref-type="fig"}. Similarly, an independent comparison of CD patients vs healthy controls resulted in significant differences for 3 antibodies, and the corresponding comparison of UC patients vs healthy controls resulted in significant differences for 2 antibodies ([Table 2](#T2){ref-type="table"}, [Fig. 2B](#F2){ref-type="fig"} and C). When CD patients and UC patients were compared, using the combined data set (IBD 1 and IBD 2), significant results were obtained for 2 proteins, namely serum amyloid protein A (SAA) and cAMP responsive element binding protein 5 (CREB5) ([Table 3](#T3){ref-type="table"}). The relative abundance of these 2 proteins is shown in [Figure 3](#F3){ref-type="fig"}. Almost all antibodies that were identified when IBD and subtypes of the disease were compared represented protein products encoded at the 163 IBD risk loci, and only 1 of them (serum amyloid protein A \[SAA\]) corresponded to the small "control" selection of known neutrophil- and inflammation-associated proteins. No significant results were observed for the comparisons of colonic CD (L2) vs UC, ileal CD (L1/L3) vs UC, and nonstricturing, nonpenetrating CD (B1) vs UC. However, the relative abundance of CREB5 differed between CD patients with complicated disease behavior, that is, stricturing (B2) or penetrating (B3) disease, and patients with ulcerative colitis. The performance characteristics (tCV, bCV, and *rho*) of the significantly altered antibodies can be found in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

###### 

Antibodies and Corresponding Proteins With Differential Abundance in Patients With IBD and Subtypes of the Disease Compared With Controls, Identified by Univariate Analyses

  Comparison   Gene        Antibody    *P*       q
  ------------ ----------- ----------- --------- ---------
  IBD-CTRL     LACC1       HPA040150   1.3E-05   3.0E-03
  IL2RA        HPA054622   4.7E-05     4.0E-03   
  LACC1        HPA061537   6.1E-05     4.0E-03   
  LNPEP        HPA043642   6.8E-05     4.0E-03   
  CNTF         HPA046534   9.1E-05     4.1E-03   
  LPXN         HPA061441   1.0E-04     4.1E-03   
  BTNL2        HPA039844   1.9E-04     6.1E-03   
  IFNAR2       HPA029229   2.2E-04     6.1E-03   
  CARD11       HPA052984   2.3E-04     6.1E-03   
  JAK2         HPA058253   3.8E-04     8.6E-03   
  PEX13        HPA061468   4.0E-04     8.6E-03   
  SLC22A5      HPA063062   5.4E-04     9.8E-03   
  IFNG         HPA063125   5.4E-04     9.8E-03   
  CD-CTRL      LACC1       HPA040150   1.8E-05   2.1E-03
  SAA          HPA059733   2.0E-05     2.1E-03   
  LNPEP        HPA043642   1.2E-04     8.4E-03   
  UC-CTRL      CNTF        HPA046534   8.3E-05   7.8E-03
               LPXN        HPA061441   8.9E-05   7.8E-03

###### 

Antibodies and Corresponding Proteins With Differential Abundance in Patients With Crohn's Disease Compared With Patients With Ulcerative Colitis in Sample Sets IBD 1 and IBD 2, Identified by Univariate Analyses

  ---------------------------------------------------------------
  Gene    Antibody    IBD 1\     IBD 2\     Meta\      Meta\
                      *P*        *P*        *P*        q
  ------- ----------- ---------- ---------- ---------- ----------
  SAA     HPA059733   8.75E-02   1.21E-01   3.45E-05   1.24E-02

  CREB5   HPA057734   2.83E-02   3.63E-02   2.04E-04   3.68E-02
  ---------------------------------------------------------------

###### 

Candidate proteins: IBD patients vs healthy controls. The boxplots show the top 4 proteins revealing significant differences in univariate group comparisons (q \< 0.01). A, Candidate proteins to differ between IBD patients (gray; n = 100) and healthy controls (CTRL; white; n = 50) are targeted by 2 LACC1 antibodies and shown on the upper panel: HPA040150 (q = 0.003) and HPA061537 (q = 0.004). On the lower panel are IL2RA (HPA054622; q = 0.003) and LNPEP (HPA043642; q = 0.003); hence, all revealed higher levels in controls compared with the combined UC and CD cases. B, When comparing CD (n = 49) and controls (n = 50), antibodies against LACC1 (HPA040150; q = 0.002) and LNPEP (HPA043642; q = 0.008) revealed higher protein levels in controls, whereas levels of SAA (HPA059733; q = 0.002) were higher in CD patients. C, When comparing UC (n = 51) with controls (n = 50), the levels for CNTF (HPA046534; q = 0.008) and LPXN (HPA061441; q = 0.008) were all lower in UC cases. The presented data are for normalized MFI values.

![](izy32602a)

![](izy32602b)

![Candidate proteins: CD vs UC. The boxplots show the proteins that differed between CD and UC patients in the 2 study sets, IBD 1 and IBD 2, with q \< 0.05. Levels of (A) SAA (HPA059733; q = 0.012) and (B) CREB5 (HPA057734; q = 0.037) were both higher in CD patients. The presented data are for normalized MFI values.](izy32603){#F3}

### Multivariate analysis {#s21}

We used a multivariate sPLS model to identify signatures of proteins differentially expressed between different groups of patients and healthy controls. Our sPLS modeling resulted in fitted sPLS models, together with optimal numbers of components (latent variables for the PLS discriminant analysis) and optimal numbers of proteins used for each model. Most proteins identified in univariate analysis as being significantly altered in IBD, CD, and UC vs controls, and in CD vs UC, were also identified in the discriminant sPLS analyses ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). In contrast to the univariate analyses, differentiating protein expression signatures between CD subtypes (colonic = L2, ileal = L1/L3, or complicated disease behavior = B2/B3) and UC were identified in the multivariate analyses ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Differently expressed protein signatures were also observed when UC patients with active disease were compared with those in remission, but no differences were observed when CD patients were stratified by disease activity ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). [Figure 4](#F4){ref-type="fig"} shows sPLS scores plots to visualize how the found biosignatures could classify the different disease classes in our data.

![sPLS scores plots of comparisons between CD patients and subgroups of CD patients, ulcerative colitis patients, and healthy controls. The sPLS scores plots visualize how the found biosignatures could classify CD patients and subgroups of CD patients, ulcerative colitis patients, and healthy controls, respectively. Abbreviations: cCD, colonic CD; iCD, ileal CD; CD_B1, nonstricturing, nonpenetrating CD; CD_B23, stricturing or penetrating CD; UC_AD, UC with active disease; UC_nonAD, UC with nonactive disease.](izy32604){#F4}

To assess the predictive accuracy of our model, hit rates were collected, and their significance assured that a leave-one-out cross-validation approach could be applied. The hit rates and their respective resampling significances, obtained in our sPLS analyses, are shown in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. All comparisons resulted in significant resampling *P* values, but the observed hit rates for CD vs UC and colonic CD vs UC were comparatively low.

LACC1-Specific Analyses {#s22}
-----------------------

A primary finding from the univariate and multivariate analyses is that the protein laccase (multicopper oxidoreductase) domain containing 1 (LACC1; previously known as C13orf31) was differentially abundant in the serum samples from IBD patients compared with healthy controls. LACC1 has been recently characterized as a novel player in IBD and inflammation, involved in the control of macrophage immunometabolic function in general, and we sought to further investigate our results. In the assays, LACC1 was detected by 2 different antibodies (HPA040150 and HPA061537), which are raised toward 2 independent epitopes, located at the N-terminal and C-terminal portions of the target protein, respectively. The obtained serum profiles from these 2 antibodies correlated with a Spearman *rho* of 0.6 ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}), indicating concordant selectivity for a common target in the matrix of human serum. The antibody HPA040150 was further validated as it shows a stronger association when comparing IBD and CD patients with controls. Western blot analyses of protein extracts from LACC1-overexpressing cells established that HPA040150 binds to denatured LACC1 ([Supplementary Fig. 3A](#sup1){ref-type="supplementary-material"}). In addition, epitope mapping analyses of the antibody were performed. Three epitopes were identified ([Supplementary Fig. 3B](#sup1){ref-type="supplementary-material"}), and a Uniprot BLAST search (100% identity and E value threshold \< 10) showed that only LACC1 matches the peptides. Finally, immuno-capture mass spectrometry analysis was conducted and confirmed that HPA040150 enriched its intended target LACC1 from serum ([Supplementary Fig. 3C](#sup1){ref-type="supplementary-material"}).

DISCUSSION {#s23}
==========

The identification of susceptibility risk variants has afforded limited success in translating genetic discoveries to enhanced knowledge of the serum proteome in IBD. Exploiting gene content from known IBD risk loci, we implemented a screen of the IBD risk proteome for the identification of serum targets eventually suitable for inclusion in follow-up biomarker discovery efforts. For this purpose, we took advantage of the HPA large antibody repository and an affinity proteomic approach, which allowed the identification of proteins showing differential abundance in healthy vs IBD serum, and in serum from different subgroups of patients. Although these proteins mostly relate to neutrophil, T-cell, and B-cell activation and function, our strategy shows that multiplexed bead-based antibody array approaches may be successfully adopted to exploit existing genetic information for the delineation of targeted proteomic studies. However, inherent limitations in this study should be noted and eventually avoided in follow-up investigations: (1) the inclusion of patients with a long disease duration may have introduced bias due to disease history; (2) there is a lack of data on endoscopic activity that may have been correlated with specific protein profiles; (3) acknowledging the exploratory nature of the our study, assays for known and expected protein signatures may not be reported; and (4) instead of using fully validated assays, the multiplexed approach may offer only insufficient analytical sensitivity and specificity, hence reducing the number of risk candidates identified in serum. Another important limitation is that we were only able to measure 204 proteins out of 1438 proteins encoded in 104 out of the 163 risk loci. Although our analyses were based on an unbiased approach, in targeting all proteins encoded at IBD risk loci, we were not able to define the exact mechanisms underlying specific predictive protein profiles or to establish a relationship between individual single nucleotide polymorphisms (SNPs) and protein expression levels (protein quantitative trait loci \[pQTLs\]), as this requires large-scale samples and analytical techniques that ensure exact relative measurement of protein levels.

Previously, only a small number of studies have aimed to identify serum proteins associated with IBD,^[@CIT0025]^ but these have been in general limited to a small number of selected targets. In recent years, some initiatives to increase our understanding have been initiated. Di Narzo et al. reported novel aging-associated proteomic traits and proteomic traits in Crohn's disease patients, corresponding to 41 distinct genes, that were significantly influenced by SNP genotypes in cis.^[@CIT0028]^ The HPA, aiming at generating and applying antibodies directed toward every human protein, represents another recent initiative. The project has been built on the systematic generation of antibodies through a predefined pipeline.^[@CIT0029]^ Here we took advantage of this large antibody repository to assay serum expression levels of proteins translated from IBD-related risk loci^[@CIT0009]^ and proteins related to inflammation including neutrophil activation. Based on this approach, we identified a number of proteins that appear to be differentially expressed in sera from IBD patients compared with healthy controls. Among the top-ranking proteins, we found targets related to cytokine signaling (IL2RA^[@CIT0033]^), immune-metabolic regulation and reactive oxygen species production (LACC1^[@CIT0034]^), antigen presentation (LNPEP^[@CIT0035]^), T-cell regulation (CARD11,^[@CIT0036]^ BTNL2,^[@CIT0037]^ and IFNG,^[@CIT0038]^), B-cell signaling (LPXN), and neurotransmitter synthesis (CNTF^[@CIT0039]^). To our knowledge, only a few of these proteins, such as CNTF^[@CIT0039]^ and LNPEP,^[@CIT0035]^ have been known to be present in sera. LACC1, whose serum expression has not been previously studied, was identified to be differentially expressed in IBD patients compared with healthy controls. Genetic variation in the *LACC1* gene has been associated with IBD, leprosy, and systemic and nonsystemic juvenile idiopathic arthritis (JIA),^[@CIT0009],\ [@CIT0040]^ whereas the corresponding protein product has been recently characterized as a master regulator of macrophage immune-metabolic function.^[@CIT0040]^ In the present study, we observed reduced serum LACC1 levels in IBD patients (primarily CD patients) compared with controls. Notably, reduced LACC1 expression has been reported to parallel the finding of hypomorphic (reduced function) *LACC1* gene variants, which are associated with increased risk of CD.^[@CIT0040]^

Lower abundance of LNPEP, an aminopeptidase involved in antigen presentation,^[@CIT0043]^ was also observed in CD patients compared with healthy controls. Interestingly, LNPEP comes from the IBD risk locus containing also the endoplasmic reticulum aminopeptidases 1 and 2 (ERAP1 and ERAP2), which are both involved in the regulation of innate immune response^[@CIT0044]^ and have well-established roles in IBD and other auto-inflammatory diseases.^[@CIT0009],\ [@CIT0045]^ Lower levels of serum expression were observed for CNTF and LPXN in UC cases compared with controls. CNTF is believed to be involved in the recruitment of macrophages,^[@CIT0046]^ whereas LPXN has been reported to have an inhibitory role in B-cell function^[@CIT0047]^ and to be involved in the development of colorectal cancer in UC patients.^[@CIT0048]^

Interestingly, the results from specific antibodies for an epitope shared by 2 isoforms of the SAA, namely A1 and A2, point to increased abundance of the SAA protein in serum from CD vs UC patients. This finding is supported by a previously reported correlation between serum SAA levels and endoscopic activity in patients with CD.^[@CIT0049]^ Similarly, increased abundance of antibodies toward CREB5, a transcription factor regulating a variety of cellular responses,^[@CIT0050]^ was observed in CD patients when compared with UC patients. This observation is consistent with the previously observed genetic association between *CREB5* and CD, but not UC,^[@CIT0009]^ and the earlier reported upregulation of CREB expression in peripheral blood mononuclear cells of CD patients.^[@CIT0051],\ [@CIT0052]^

By implementing an sPLS model, we were able to identify signatures (ie, combinations) of proteins associated with IBD and its subtypes CD and UC. Based on these signatures, a predictive accuracy of 0.76--0.83 was observed when compared with healthy controls. The accuracy of our model dropped when different subtypes of IBD were compared against each other, even though our protein signatures remained significant, indicating that the found protein signatures were truly discriminative for all tested comparisons. Interestingly, a better accuracy was observed for serum profiles from ileal rather than colonic CD, when these were compared with UC profiles. This observation may add further support to recent genetic data, indicating that the genetic distance between ileal CD and UC is actually larger than that between colonic CD and UC.^[@CIT0004]^ Differentially expressed signatures of proteins were also observed between CD patients with complicated disease behavior (stricturing \[B2\] or penetrating disease \[B3\]) and CD patients with nonstricturing, nonpenetrating disease (B1), and with UC patients. This finding may seem contrary to that of Cleynen et al., who reported little or no genetic association with disease behavior.^[@CIT0004]^ However, our findings might have been biased by differences in other phenotypic characteristics such as disease location and age at onset.

In conclusion, we took advantage of a large repository of antibodies to exploit genetic information from IBD risk loci to identify disease-associated serum profiles. Among others, we report interesting results for LACC1, a novel immune player in IBD that shows downregulated expression in CD patients. A number of additional candidate proteins have the potential to be prioritized as selected targets in future biomarker discovery efforts in IBD.

SUPPLEMENTARY DATA {#s24}
==================

Supplementary data are available at *Inflammatory Bowel Diseases* online.

###### 

Click here for additional data file.
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